We are live on
!
Find out more
BM
Bridger Management Portfolio holdings
AUM
$128M
1-Year Est. Return
9.54%
This Fund
S&P 500
This Quarter
Est. Return
+19.36%
1 Year Est. Return
+9.54%
3 Year Est. Return
+98.31%
5 Year Est. Return
+125.76%
10 Year Est. Return
+911.97%
AUM
$1.75B
AUM Growth
+$314M
(+22%)
Cap. Flow
+$99.9M
Cap. Flow
% of AUM
5.7%
Top 10 Holdings %
Top 10 Hldgs %
44.11%
Holding
42
New
6
Increased
14
Reduced
10
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Teva Pharmaceuticals
TEVA
|
+$62.7M |
| 2 |
Humana
HUM
|
+$56.8M |
| 3 |
SGI
Somnigroup International
SGI
|
+$45.4M |
| 4 |
Morgan Stanley
MS
|
+$40.4M |
| 5 |
Adient
ADNT
|
+$34.6M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$56.8M |
| 2 |
AET
Aetna Inc
AET
|
+$51.3M |
| 3 |
Merck
MRK
|
+$50.9M |
| 4 |
KSU
Kansas City Southern
KSU
|
+$38.2M |
| 5 |
Incyte
INCY
|
+$29.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 53.58% |
| 2 | Consumer Discretionary | 11.84% |
| 3 | Communication Services | 7.08% |
| 4 | Industrials | 5.75% |
| 5 | Consumer Staples | 5.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SHPG
1
DELISTED
Shire pic
SHPG
| $96.3M | 5.5% |
552,977
+163,996
| +42% | +$28.6M |
|
2
Post Holdings
POST
$4.15B
| $93.8M | 5.35% |
1,638,123
| – | – |
|
|
MDCO
3
DELISTED
Medicines Co
MDCO
| $88.9M | 5.07% |
1,818,488
+193,974
| +12% | +$8.85M |
|
|
EVHC
4
DELISTED
Envision Healthcare Holdings Inc
EVHC
| $87M | 4.96% |
1,419,083
+224,540
| +19% | +$15.1M |
|
|
WMGI
5
DELISTED
Wright Medical Group Inc
WMGI
| $82.6M | 4.71% |
2,655,256
-534,820
| -17% | -$14.5M |
|
6
Gilead Sciences
GILD
$162B
| $69.7M | 3.98% |
1,025,775
+314,355
| +44% | +$22.1M |
|
7
Nektar Therapeutics
NKTR
$2.38B
| $68.9M | 3.93% |
195,817
-67,162
| -26% | -$15.1M |
|
|
AGN
8
DELISTED
Allergan plc
AGN
| $66.8M | 3.81% |
279,799
-40,672
| -13% | -$9.47M |
|
9
Centene
CNC
$30.7B
| $60M | 3.42% |
1,683,708
-353,318
| -17% | -$11.8M |
|
|
10
Teva Pharmaceuticals
TEVA
$40.9B
| $59M | 3.37% |
+1,838,440
| New | +$62.7M |
|
11
Armstrong World Industries
AWI
$7.32B
| $57.6M | 3.29% |
1,251,456
+90,000
| +8% | +$3.81M |
|
|
12
Humana
HUM
$44.1B
| $56.7M | 3.23% |
+274,908
| New | +$56.8M |
|
13
Labcorp
LH
$25.5B
| $56.3M | 3.21% |
457,132
+229,166
| +101% | +$27.1M |
|
14
MGM Resorts International
MGM
$11.4B
| $55.4M | 3.16% |
2,022,700
-784,877
| -28% | -$21.8M |
|
15
TG Therapeutics
TGTX
$8.01B
| $53.9M | 3.07% |
4,622,749
-298,310
| -6% | -$2.14M |
|
16
GoDaddy
GDDY
$10.5B
| $50.7M | 2.89% |
1,336,589
+152,880
| +13% | +$5.54M |
|
17
Meta Platforms (Facebook)
META
$1.4T
| $45.7M | 2.61% |
321,505
| – | – |
|
18
Charter Communications
CHTR
$17.4B
| $45.2M | 2.58% |
138,087
-54,361
| -28% | -$17.3M |
|
|
GRUB
19
DELISTED
Just Eat Takeaway.com N.V. American Depositary Shares
GRUB
| $43.1M | 2.46% |
655,569
+123,459
| +23% | +$9.12M |
|
20
VeriSign
VRSN
$26.1B
| $42.3M | 2.41% |
485,036
+99,025
| +26% | +$8.23M |
|
|
SGI
21
Somnigroup International
SGI
$14B
| $41M | 2.34% |
+3,532,012
| New | +$45.4M |
|
|
22
Morgan Stanley
MS
$332B
| $39M | 2.23% |
+910,359
| New | +$40.4M |
|
|
23
Adient
ADNT
$1.63B
| $38.3M | 2.19% |
+527,133
| New | +$34.6M |
|
24
Alnylam Pharmaceuticals
ALNY
$27.1B
| $37.3M | 2.13% |
727,091
+8,476
| +1% | +$392K |
|
|
25
Incyte
INCY
$24.4B
| $37.1M | 2.12% |
277,674
-232,308
| -46% | -$29.6M |
|
Similar funds
SHFC
IUC
PC
SIM
PIA
S
CF
BC
Bridger Management's Q1 2017 Portfolio in Review
As of Q1 2017, Bridger Management held 42 positions worth $1.75B, up 22% from $1.44B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Bridger Management deployed $99.9M of net new capital in Q1 2017, opening 6 new positions and adding to 14 existing holdings. Its largest new stake was Teva Pharmaceuticals: 1,838,440 shares worth $59M.
By sector, the portfolio is most concentrated in Healthcare at 54% of assets, up from 51% a quarter earlier, followed by Consumer Discretionary and Communication Services.
On the sell side, the largest reduction was Incyte, an estimated $29.6M trimmed.
- Bridger Management's largest Q1 2017 buy was Teva Pharmaceuticals: 1,838,440 shares worth $59M.
- Bridger Management added most to Shire pic in Q1 2017, an estimated $28.6M increase.
- Bridger Management's biggest Q1 2017 reduction was Incyte, cutting an estimated $29.6M.
- Bridger Management fully exited UnitedHealth in Q1 2017, selling an estimated $56.8M.
- Bridger Management's ten largest holdings make up 44% of its $1.75B portfolio in Q1 2017.
- Bridger Management opened 6 new positions and closed 5 in Q1 2017.
- Bridger Management's portfolio value rose 22% quarter-over-quarter to $1.75B.
Based on Bridger Management's 13F filing for Q1 2017, filed 15 May 2017.